Aug. 23, 2023 – Since the FDA approved once-weekly semaglutide injection in 2021 for chronic weight management for adults with obesity or overweight with at least one weight-related condition, a multibillion-dollar market for anti-obesity medications has followed. Injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) and its counterpart semaglutide 1 mg (Ozempic), approved to treat type 2 diabetes, are associated with weight loss of as much as 15% to 20% for some patients. The GLP-1 receptor agonists now dominate headlines — and celebrity weight loss speculation — in the mainstream press.
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…
AUDIO – A GIANT IS GONE – Dec. 10, 2024 - Nikki Giovanni, the poet,…